These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

599 related articles for article (PubMed ID: 15930312)

  • 21. Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: Intracellular mechanisms.
    Shankar S; Singh TR; Srivastava RK
    Prostate; 2004 Sep; 61(1):35-49. PubMed ID: 15287092
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Triptolide sensitizes resistant cholangiocarcinoma cells to TRAIL-induced apoptosis.
    Panichakul T; Intachote P; Wongkajorsilp A; Sripa B; Sirisinha S
    Anticancer Res; 2006; 26(1A):259-65. PubMed ID: 16475706
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21(waf1).
    Chopin V; Slomianny C; Hondermarck H; Le Bourhis X
    Exp Cell Res; 2004 Aug; 298(2):560-73. PubMed ID: 15265702
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
    Hesry V; Piquet-Pellorce C; Travert M; Donaghy L; Jégou B; Patard JJ; Guillaudeux T
    Prostate; 2006 Jun; 66(9):987-95. PubMed ID: 16541419
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY; Dai Y; Grant S
    Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells.
    Johnson TR; Stone K; Nikrad M; Yeh T; Zong WX; Thompson CB; Nesterov A; Kraft AS
    Oncogene; 2003 Aug; 22(32):4953-63. PubMed ID: 12902978
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells.
    Earel JK; VanOosten RL; Griffith TS
    Cancer Res; 2006 Jan; 66(1):499-507. PubMed ID: 16397266
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.
    Koschny R; Holland H; Sykora J; Haas TL; Sprick MR; Ganten TM; Krupp W; Bauer M; Ahnert P; Meixensberger J; Walczak H
    Clin Cancer Res; 2007 Jun; 13(11):3403-12. PubMed ID: 17545549
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
    Cuello M; Ettenberg SA; Nau MM; Lipkowitz S
    Gynecol Oncol; 2001 Jun; 81(3):380-90. PubMed ID: 11371126
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of interleukin 8 as an inhibitor of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in the ovarian carcinoma cell line OVCAR3.
    Abdollahi T; Robertson NM; Abdollahi A; Litwack G
    Cancer Res; 2003 Aug; 63(15):4521-6. PubMed ID: 12907626
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Signaling events triggered by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): caspase-8 is required for TRAIL-induced apoptosis.
    Seol DW; Li J; Seol MH; Park SY; Talanian RV; Billiar TR
    Cancer Res; 2001 Feb; 61(3):1138-43. PubMed ID: 11221844
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Implication of multiple mechanisms in apoptosis induced by the synthetic retinoid CD437 in human prostate carcinoma cells.
    Sun SY; Yue P; Lotan R
    Oncogene; 2000 Sep; 19(39):4513-22. PubMed ID: 11002424
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sensitization to gimatecan-induced apoptosis by tumor necrosis factor-related apoptosis inducing ligand in prostate carcinoma cells.
    Perego P; Ciusani E; Gatti L; Carenini N; Corna E; Zunino F
    Biochem Pharmacol; 2006 Mar; 71(6):791-8. PubMed ID: 16438941
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human agonistic antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2 induces cytotoxicity and apoptosis in prostate cancer and bladder cancer cells.
    Shimada O; Wu X; Jin X; Nouh MA; Fiscella M; Albert V; Matsuda T; Kakehi Y
    Urology; 2007 Feb; 69(2):395-401. PubMed ID: 17320696
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in androgen-independent prostate cancer cells.
    Yu R; Mandlekar S; Ruben S; Ni J; Kong AN
    Cancer Res; 2000 May; 60(9):2384-9. PubMed ID: 10811114
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL.
    Voelkel-Johnson C; King DL; Norris JS
    Cancer Gene Ther; 2002 Feb; 9(2):164-72. PubMed ID: 11857034
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Caspase-mediated p65 cleavage promotes TRAIL-induced apoptosis.
    Kim HS; Chang I; Kim JY; Choi KH; Lee MS
    Cancer Res; 2005 Jul; 65(14):6111-9. PubMed ID: 16024612
    [TBL] [Abstract][Full Text] [Related]  

  • 38. P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5.
    Park SJ; Wu CH; Choi MR; Najafi F; Emami A; Safa AR
    Biochem Pharmacol; 2006 Jul; 72(3):293-307. PubMed ID: 16753135
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genistein sensitizes human hepatocellular carcinoma cells to TRAIL-mediated apoptosis by enhancing Bid cleavage.
    Jin CY; Park C; Moon SK; Kim GY; Kwon TK; Lee SJ; Kim WJ; Choi YH
    Anticancer Drugs; 2009 Sep; 20(8):713-22. PubMed ID: 19617819
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction and regulation of tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand-mediated apoptosis in renal cell carcinoma.
    Griffith TS; Fialkov JM; Scott DL; Azuhata T; Williams RD; Wall NR; Altieri DC; Sandler AD
    Cancer Res; 2002 Jun; 62(11):3093-9. PubMed ID: 12036919
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.